Abstract

Hyperthyroidism is associated with an increase in both osteoblast and osteoclast activity. We have previously shown that, in vitro, osteoclasts do not respond directly to tri-iodothyronine to increase bone resorption but that the effect is mediated by another bone cell, probably the osteoblast. To investigate this issue further we have studied the isoform-specific expression of thyroid receptor (TR) protein in human osteoclasts derived from an osteoclastoma (giant cell tumour of bone) and the expression of TR mRNA and protein in the osteoblastic cell lines MG 63 and UMR 106. Three major TR receptor variants have been described; TR alpha 1 and TR beta are functional receptors whereas c-erbA alpha 2 is a non-functional variant. Northern blot analysis using [32P]-cDNA probes against human TR alpha 1, c-erbA alpha 2 and TR beta demonstrated specific binding of these probes to mRNA from MG 63 and UMR 106. mRNA for all three receptor variants was observed in both cell lines, in UMR 106 multiple mRNA transcripts were present for TR alpha 1 and TR beta. Immunohistochemical staining with antibodies recognizing a common TR alpha epitope and specific c-erbA alpha 2 and TR beta epitopes extended these observations by demonstrating receptor protein in both osteoblasts and osteoclasts. These findings are consistent with previous observations of TR expression in osteoblast-like-cells and are the first direct demonstration of TR in osteoclasts.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.